Neuralink Corp. develops implantable brain-computer interfaces that enable direct neural control of external devices through advanced signal processing technology. Founded in 2016 and headquartered in Fremont, California, the company has emerged as a leading innovator in the nascent brain-computer interface market. Neuralink has achieved significant technological milestones, including successful human trials and FDA approval for clinical studies, while securing a valuation of $9 billion through private funding rounds. The company currently focuses on advancing its neural implant technology for medical applications, particularly targeting paralysis and neurological conditions, while developing the foundational infrastructure for broader human-computer integration capabilities.